Akanda Corp. Common Shares (AKAN) Stock: Buy, Sell, or Hold?
AKAN - Akanda Corp. Common Shares
$3.07
0.07 (2.33%)
▲
5d:
-16.35%
30d:
-43.04%
90d:
-80.05%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Get Alerted When AKAN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AKAN is down 16.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AKAN is down 16.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AKAN is currently trading at $3.07, which is considered oversold relative to its 30-day fair value range of $3.46 to $5.19.
Technical Outlook: Technically, AKAN is in a downtrend. The price is currently testing key support at $3.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AKAN scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AKAN is in a downtrend. The price is currently testing key support at $3.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AKAN scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.46 -
$5.19
Company Quality Score
42/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.46 -
$5.19
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.00
Resistance Level
$4.44
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Revenue Growth (YoY)
21.9%
Share & Embed Analysis
Last updated: September 13, 2026 9:30 AM ET
Data refreshes hourly during market hours. Next update: 10:30 AM
Data refreshes hourly during market hours. Next update: 10:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKAN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
